Page last updated: 2024-12-10

seglitide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311430
CHEMBL ID311695
SCHEMBL ID151244
MeSH IDM0121676

Synonyms (37)

Synonym
CHEMBL311695 ,
(3s,6s,9s,12r,15s,18s)-9-(4-amino-butyl)-3-benzyl-15-(4-hydroxy-benzyl)-12-(1h-indol-3-ylmethyl)-6-isopropyl-1,18-dimethyl-1,4,7,10,13,16hexaaza-cyclooctadecane-2,5,8,11,14,17-hexaone
bdbm50051568
mk678
(3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-15-[(4-hydroxyphenyl)methyl]-12-(1h-indol-3-ylmethyl)-1,18-dimethyl-3-(phenylmethyl)-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone
gtpl2051
l-363586
mk-678
EU-0101105
LOPAC0_001105
seglitide
cyclo(n-methyl-l-alanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-phenylalanyl)
seglitidum [latin]
cyclic(n-methyl-l-alanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-phenylalanyl)
seglitida [spanish]
seglitide [inn]
mk 678
S 1316
(3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1h-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone
CCG-205181
unii-5p57r7ir6j
seglitida
81377-02-8
seglitidum
5p57r7ir6j ,
cyclo(n-methyl-ala-tyr-d-trp-lys-val-phe)
SCHEMBL151244
cyclo(d-trp-lys-val-phe-n-me-ala-tyr)
NPJIOCBFOAHEDO-AVWFULIKSA-N
AKOS024456805
sr-01000076118
SR-01000076118-2
(3s,6s,9s,12r,15s,18s)-12-((1h-indol-3-yl)methyl)-9-(4-aminobutyl)-3-benzyl-15-(4-hydroxybenzyl)-6-isopropyl-1,18-dimethyl-1,4,7,10,13,16-hexaazacyclooctadecane-2,5,8,11,14,17-hexaone
cyclo-(n-me-ala-tyr-d-trp-lys-val-phe)
cyclo(n-me-ala-tyr-d-trp-lys-val-phe)
Q27088775
GLXC-26287

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The metabolic clearance rate of the analogue (approximately 300 ml/min) was 1/6 that previously reported for somatostatin (approximately 2000 ml/min) and its half-life was approximately 20 times as great as that reported for somatostatin (45 vs 2 min)."( Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus.
Gerich, J; Gottesman, I; Tobert, J; Vandlen, R, 1986
)
0.27

Bioavailability

ExcerptReferenceRelevance
" The analog is found to be quite stable in the blood and in the gastrointestinal tract, but the bioavailability after oral administration is only 1-3%."( A super active cyclic hexapeptide analog of somatostatin.
Brady, SF; Colton, CD; Curley, P; Freidinger, RM; Nutt, RF; Paleveda, WJ; Perlow, DS; Saperstein, R; Veber, DF; Zacchei, AG, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorHomo sapiens (human)IC50 (µMol)1.00000.00000.09526.8130AID208432
Somatostatin receptor type 1Homo sapiens (human)IC50 (µMol)1.00000.00010.00130.0022AID652542
Somatostatin receptor type 1Homo sapiens (human)Ki1.00000.00030.41232.3920AID203390
Somatostatin receptor type 2Homo sapiens (human)IC50 (µMol)0.00160.00040.00240.0140AID652543
Somatostatin receptor type 2Homo sapiens (human)Ki0.00020.00000.40914.7200AID203087; AID203409
Somatostatin receptor type 4Homo sapiens (human)IC50 (µMol)1.00000.00010.00210.0042AID652545
Somatostatin receptor type 4Homo sapiens (human)Ki2.10000.00060.27333.2000AID203237; AID203570
Somatostatin receptor type 3Homo sapiens (human)IC50 (µMol)0.10500.00040.11100.8800AID652544
Somatostatin receptor type 3Homo sapiens (human)Ki0.03160.00010.03200.1290AID203551
Somatostatin receptor type 5Homo sapiens (human)IC50 (µMol)0.08100.00020.04720.3930AID652546
Somatostatin receptor type 5Homo sapiens (human)Ki0.01260.00010.44794.0700AID203709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerSomatostatin receptor type 1Homo sapiens (human)
glutamate receptor signaling pathwaySomatostatin receptor type 1Homo sapiens (human)
spermatogenesisSomatostatin receptor type 1Homo sapiens (human)
negative regulation of cell population proliferationSomatostatin receptor type 1Homo sapiens (human)
cerebellum developmentSomatostatin receptor type 1Homo sapiens (human)
forebrain developmentSomatostatin receptor type 1Homo sapiens (human)
somatostatin signaling pathwaySomatostatin receptor type 1Homo sapiens (human)
response to starvationSomatostatin receptor type 1Homo sapiens (human)
cellular response to leukemia inhibitory factorSomatostatin receptor type 1Homo sapiens (human)
cellular response to estradiol stimulusSomatostatin receptor type 1Homo sapiens (human)
neuropeptide signaling pathwaySomatostatin receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerSomatostatin receptor type 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaySomatostatin receptor type 2Homo sapiens (human)
spermatogenesisSomatostatin receptor type 2Homo sapiens (human)
negative regulation of cell population proliferationSomatostatin receptor type 2Homo sapiens (human)
cerebellum developmentSomatostatin receptor type 2Homo sapiens (human)
peristalsisSomatostatin receptor type 2Homo sapiens (human)
forebrain developmentSomatostatin receptor type 2Homo sapiens (human)
somatostatin signaling pathwaySomatostatin receptor type 2Homo sapiens (human)
response to starvationSomatostatin receptor type 2Homo sapiens (human)
cellular response to glucocorticoid stimulusSomatostatin receptor type 2Homo sapiens (human)
cellular response to estradiol stimulusSomatostatin receptor type 2Homo sapiens (human)
neuropeptide signaling pathwaySomatostatin receptor type 2Homo sapiens (human)
G protein-coupled receptor signaling pathwaySomatostatin receptor type 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerSomatostatin receptor type 4Homo sapiens (human)
negative regulation of cell population proliferationSomatostatin receptor type 4Homo sapiens (human)
cell migrationSomatostatin receptor type 4Homo sapiens (human)
forebrain developmentSomatostatin receptor type 4Homo sapiens (human)
somatostatin signaling pathwaySomatostatin receptor type 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSomatostatin receptor type 4Homo sapiens (human)
positive regulation of arachidonic acid secretionSomatostatin receptor type 4Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaySomatostatin receptor type 4Homo sapiens (human)
neuropeptide signaling pathwaySomatostatin receptor type 4Homo sapiens (human)
cellular response to glucocorticoid stimulusSomatostatin receptor type 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerSomatostatin receptor type 3Homo sapiens (human)
cell-cell signalingSomatostatin receptor type 3Homo sapiens (human)
spermatogenesisSomatostatin receptor type 3Homo sapiens (human)
negative regulation of cell population proliferationSomatostatin receptor type 3Homo sapiens (human)
hormone-mediated apoptotic signaling pathwaySomatostatin receptor type 3Homo sapiens (human)
cerebellum developmentSomatostatin receptor type 3Homo sapiens (human)
forebrain developmentSomatostatin receptor type 3Homo sapiens (human)
somatostatin signaling pathwaySomatostatin receptor type 3Homo sapiens (human)
response to starvationSomatostatin receptor type 3Homo sapiens (human)
cellular response to glucocorticoid stimulusSomatostatin receptor type 3Homo sapiens (human)
cellular response to estradiol stimulusSomatostatin receptor type 3Homo sapiens (human)
neuropeptide signaling pathwaySomatostatin receptor type 3Homo sapiens (human)
G protein-coupled receptor signaling pathwaySomatostatin receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerSomatostatin receptor type 5Homo sapiens (human)
negative regulation of cell population proliferationSomatostatin receptor type 5Homo sapiens (human)
positive regulation of cytokinesisSomatostatin receptor type 5Homo sapiens (human)
somatostatin signaling pathwaySomatostatin receptor type 5Homo sapiens (human)
cellular response to glucocorticoid stimulusSomatostatin receptor type 5Homo sapiens (human)
neuropeptide signaling pathwaySomatostatin receptor type 5Homo sapiens (human)
regulation of insulin secretionSomatostatin receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
somatostatin receptor activitySomatostatin receptor type 1Homo sapiens (human)
protein bindingSomatostatin receptor type 1Homo sapiens (human)
neuropeptide bindingSomatostatin receptor type 1Homo sapiens (human)
protein bindingSomatostatin receptor type 2Homo sapiens (human)
PDZ domain bindingSomatostatin receptor type 2Homo sapiens (human)
somatostatin receptor activitySomatostatin receptor type 2Homo sapiens (human)
neuropeptide bindingSomatostatin receptor type 2Homo sapiens (human)
protein bindingSomatostatin receptor type 4Homo sapiens (human)
somatostatin receptor activitySomatostatin receptor type 4Homo sapiens (human)
neuropeptide bindingSomatostatin receptor type 4Homo sapiens (human)
somatostatin receptor activitySomatostatin receptor type 3Homo sapiens (human)
signaling receptor bindingSomatostatin receptor type 3Homo sapiens (human)
protein bindingSomatostatin receptor type 3Homo sapiens (human)
neuropeptide bindingSomatostatin receptor type 3Homo sapiens (human)
G protein-coupled receptor activitySomatostatin receptor type 3Homo sapiens (human)
protein bindingSomatostatin receptor type 5Homo sapiens (human)
neuropeptide bindingSomatostatin receptor type 5Homo sapiens (human)
somatostatin receptor activitySomatostatin receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSomatostatin receptor type 1Homo sapiens (human)
plasma membraneSomatostatin receptor type 1Homo sapiens (human)
neuron projectionSomatostatin receptor type 1Homo sapiens (human)
cytosolSomatostatin receptor type 2Homo sapiens (human)
plasma membraneSomatostatin receptor type 2Homo sapiens (human)
neuron projectionSomatostatin receptor type 2Homo sapiens (human)
plasma membraneSomatostatin receptor type 2Homo sapiens (human)
plasma membraneSomatostatin receptor type 4Homo sapiens (human)
neuron projectionSomatostatin receptor type 4Homo sapiens (human)
plasma membraneSomatostatin receptor type 4Homo sapiens (human)
plasma membraneSomatostatin receptor type 3Homo sapiens (human)
ciliumSomatostatin receptor type 3Homo sapiens (human)
ciliary membraneSomatostatin receptor type 3Homo sapiens (human)
non-motile ciliumSomatostatin receptor type 3Homo sapiens (human)
neuron projectionSomatostatin receptor type 3Homo sapiens (human)
plasma membraneSomatostatin receptor type 3Homo sapiens (human)
plasma membraneSomatostatin receptor type 5Homo sapiens (human)
plasma membraneSomatostatin receptor type 5Homo sapiens (human)
neuron projectionSomatostatin receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID195175In vitro GH release inhibiting potency on anterior pitutaries from adult male rats, relative to somatostatin1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Three-dimensional quantitative structure-activity relationships of somatostatin analogues. 1. Comparative molecular field analysis of growth hormone release-inhibiting potencies.
AID652542Binding affinity to human sst1 by in vitro receptor autoradiography assay2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
AID203409Binding affinity towards human Somatostatin receptor type 2 (sst2) using Tyr11-[125I]-SRIF as radioligand was determined in CHO cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
AID203709Binding affinity towards human Somatostatin receptor type 5 (sst5) using Tyr11-[125I]-SRIF as radioligand was determined in COS cell2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
AID203237In vitro binding affinity at somatostatin receptor 4 in transfected BHK cells using [125 I]Tyr11-SRIF-14 as radioligand1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas.
AID203570Binding affinity towards human Somatostatin receptor type 4 (sst4) using Tyr11-[125I]-SRIF as radioligand was determined in CHO cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
AID203087In vitro binding affinity at somatostatin 2 receptor in transfected HEK 293 cell using [125 I]Tyr11-SRIF-14 as radioligand1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas.
AID652540Inhibition of sst2 in rat trachea assessed as effect on EFS-induced CGRP release in stimulated and poststimulated tracheal fraction at 500 nM after 8 mins by radioimmunoassay technique relative to control2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
AID652543Binding affinity to human sst2 by in vitro receptor autoradiography assay2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
AID208432Inhibition of Tachykinin receptor 11996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.
AID203551Binding affinity towards human Somatostatin receptor type 3 (sst3) using Tyr11-[125I]-SRIF as radioligand was determined in CHO cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
AID203390Binding affinity towards human Somatostatin receptor type 1 (sst1) using Tyr11-[125I]-SRIF as radioligand was determined in CHO cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
AID652545Binding affinity to human sst4 by in vitro receptor autoradiography assay2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
AID652544Binding affinity to human sst3 by in vitro receptor autoradiography assay2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID652546Binding affinity to human sst5 by in vitro receptor autoradiography assay2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1346413Human SST5 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346413Human SST5 receptor (Somatostatin receptors)1998Proceedings of the National Academy of Sciences of the United States of America, Sep-01, Volume: 95, Issue:18
Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.
AID1346424Human SST2 receptor (Somatostatin receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 360, Issue:5
Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
AID1346332Human SST3 receptor (Somatostatin receptors)1998Proceedings of the National Academy of Sciences of the United States of America, Sep-01, Volume: 95, Issue:18
Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.
AID1346413Human SST5 receptor (Somatostatin receptors)1994Endocrinology, Dec, Volume: 135, Issue:6
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
AID1346424Human SST2 receptor (Somatostatin receptors)1996Metabolism: clinical and experimental, Aug, Volume: 45, Issue:8 Suppl 1
Binding properties of somatostatin receptor subtypes.
AID1346332Human SST3 receptor (Somatostatin receptors)1994Endocrinology, Dec, Volume: 135, Issue:6
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
AID1346332Human SST3 receptor (Somatostatin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 357, Issue:5
[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
AID1346332Human SST3 receptor (Somatostatin receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 360, Issue:5
Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
AID1346413Human SST5 receptor (Somatostatin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 357, Issue:5
[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
AID1346404Mouse SST3 receptor (Somatostatin receptors)1993Molecular pharmacology, Jun, Volume: 43, Issue:6
Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
AID1346419Rat SST2 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346424Human SST2 receptor (Somatostatin receptors)1998European journal of pharmacology, May-08, Volume: 348, Issue:2-3
[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
AID1346424Human SST2 receptor (Somatostatin receptors)1994Endocrinology, Dec, Volume: 135, Issue:6
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
AID1346413Human SST5 receptor (Somatostatin receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 360, Issue:5
Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
AID1346413Human SST5 receptor (Somatostatin receptors)1998European journal of pharmacology, May-08, Volume: 348, Issue:2-3
[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
AID1346311Mouse SST2 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346420Rat SST5 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346321Rat SST3 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346413Human SST5 receptor (Somatostatin receptors)1996Metabolism: clinical and experimental, Aug, Volume: 45, Issue:8 Suppl 1
Binding properties of somatostatin receptor subtypes.
AID1346332Human SST3 receptor (Somatostatin receptors)1996Metabolism: clinical and experimental, Aug, Volume: 45, Issue:8 Suppl 1
Binding properties of somatostatin receptor subtypes.
AID1346424Human SST2 receptor (Somatostatin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 357, Issue:5
[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
AID1346397Mouse SST5 receptor (Somatostatin receptors)2000Neuropharmacology, Jun-08, Volume: 39, Issue:8
Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
AID1346424Human SST2 receptor (Somatostatin receptors)1998Proceedings of the National Academy of Sciences of the United States of America, Sep-01, Volume: 95, Issue:18
Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (13.89)18.7374
1990's46 (63.89)18.2507
2000's12 (16.67)29.6817
2010's4 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.27 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (16.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.70%)5.53%
Reviews2 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (94.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]